Browsing Tag
BIMZELX
3 posts
UCB shares surge as Bimzelx turns a mid-teens outlook into 20%-plus growth
UCB has upgraded 2026 revenue growth to the low twenties and adjusted EBITDA growth to the low-to-mid forties as Bimzelx demand and pricing outperform expectations in the United States.
UCB’s BIMZELX shows sustained inflammation control at three years in psoriatic arthritis and axial spondyloarthritis
Discover how UCB’s BIMZELX three-year data show lasting inflammation control in PsA and axSpA—find out what’s next for the treatment landscape.
UCB announces positive 48-week results for BIMZELX in Hidradenitis Suppurativa studies
At the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California, UCB, a leading global…